Clinical Trials

15 enrolled 9 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02362035 2025-12-11

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03769532 2025-08-24

PEMAZA

Phase 2 Terminated

26 enrolled

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute

NCT03512405 2025-05-30

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

36 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03219450 2025-05-22

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Phase 1 Recruiting

15 enrolled

Leukemia, Leukemia, Lymphoid

NCT03035331 2025-05-16

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

11 enrolled 12 charts

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03286114 2025-05-11

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Phase 1 Terminated

16 enrolled 13 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03153202 2024-11-19

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Phase 1/2 Active not recruiting

23 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

26 enrolled 14 charts

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02768792 2024-09-25

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

38 enrolled 14 charts

Phase EARLY_PHASE1 Completed

Leukemia, Myeloid, Acute

NCT02981914 2024-04-22

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

12 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04478695 2024-03-08

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

1 enrolled 2 charts

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Recurrence, Leukemia, Myeloid, Acute

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

65 enrolled 21 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02771197 2023-09-28

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

20 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT02845297 2023-03-09

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

67 enrolled 10 charts

Leukemia, Myeloid, Acute

NCT02996474 2022-12-28

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

10 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT04605614 2022-06-09

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Phase 1 Withdrawn

Hematologic Neoplasms

NCT03144245 2021-10-12

Study of AMV564 in Patients With AML

Phase 1 Completed

53 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02708641 2021-08-10

A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

12 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT03605589 2021-04-01

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Phase 1 Withdrawn

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT02767934 2020-08-20

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

Phase 2 Terminated

12 enrolled 12 charts

Burkitt Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04016116 2020-05-27

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Phase 2 Withdrawn

Phase EARLY_PHASE1 Withdrawn

Neoplasms, Hematologic Neoplasms

NCT03291353 2019-04-19

Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia